Therapeutic drug monitoring of phenytoin is carried out to ensure effective and safe levels. Some of the factors complicating phenytoin dosing include a narrow therapeutic window, high degree of protein binding, and nonlinear pharmacokinetics. However, serum drug levels should only be taken when there is a clear indication to guide patient management. Scenarios where monitoring levels may be clinically useful include: (1) establishing an individual therapeutic concentration, (2) aiding in diagnosis of clinical toxicity, (3) assessing patient compliance, and (4) guiding dosage adjustments in patients likely to have greater pharmacokinetic variability. This paper aims to provide an overview on of the correct timing and interpretation of phenytoin levels. It will also address phenytoin dosing, other monitoring parameters, and management of phenytoin adverse effects.
WHAT Is PHENYTOIN?
Phenytoin is an anticonvulsant licensed for the management of generalised tonic-clonic (grandmal) seizures and complex partial (psychomotor, temporal lobe) seizures 1 . It is also approved by the United States Federal Drug Authority for the prevention and treatment of seizures occurring during or after neurosurgery 2 .
WHY Is THErAPEUTIc DrUG MONITOrING OF PHENYTOIN NEcEssArY?
Phenytoin has a narrow therapeutic window hence a fine balance must be found between efficacy and dose-related side effects 3 . Since phenytoin is highly protein-bound and free (unbound) phenytoin is the component producing the pharmacological effect, any factor which changes the protein binding of phenytoin would be expected to alter the free drug levels. As such, interactions with other drugs (drug-drug interactions) or with diseases e.g. renal impairment, uraemia, and critical illness (drugdisease interactions) may give rise to changes in phenytoin pharmacokinetics and/or efficacy and toxicity.
Furthermore, phenytoin demonstrates non-linear pharmacokinetics even within the therapeutic range. The enzyme system involved in phenytoin metabolism gradually becomes saturated, resulting in a decrease in the rate of elimination of phenytoin as the dose is increased 4 . This means that once the enzyme system becomes saturated with phenytoin, even a small change in dose can lead to a large change in phenytoin levels. The phenytoin concentrations leading to enzyme saturation vary considerably between individuals. Thus, patients taking the same dosage can have up to a 50-fold difference in plasma phenytoin concentration (inter-individual variability) 4 . For these reasons, monitoring of phenytoin levels may be clinically valuable to ensure therapeutic efficacy in individual patients.
Laboratories in Singapore commonly monitor total phenytoin concentration in blood. Free phenytoin levels are available in some facilities worldwide, but access remains limited and costly. Furthermore, studies show that the use of total phenytoin levels is adequate in most clinical cases 5, 6 and free phenytoin levels may be required only for patients expected to have altered protein binding or where adverse effects are experienced at unexpectedly low total phenytoin concentrations 6 . To Establish an Individual Therapeutic Concentration The reference range for phenytoin levels may not be applicable to all patients. The difference can be due to seizure type, the severity of the underlying disorder, or genetic abnormalities. Ultimately, phenytoin therapy may be best guided by the identification of the "individual therapeutic concentration" -the concentration which has been found to produce optimal response in the individual patient (i.e. a balance between seizure control and acceptable adverse effects).
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To Aid in Diagnosis of Clinical Toxicity
Phenytoin toxicity may be variable in presentation (Table 1) . Some dose-related adverse effects may mimic symptoms of other diseases. Drug levels may assist in ruling out phenytoin toxicity as a differential diagnosis.
To Assess Patient Compliance (e.g. Situations of Uncontrolled or Breakthrough Seizures)
Breakthrough seizures or uncontrolled epilepsy may be due to a genuinely refractory disease or intercurrent illness. However, patient noncompliance leading to sub-therapeutic phenytoin levels is common enough that checking the phenytoin level to ensure effective drug concentrations would be a logical first step in patients presenting with breakthrough seizures or worsening epilepsy.
To Guide Dosage Adjustments in Situations Associated with Greater Pharmacokinetic Variability
Factors altering the pharmacokinetics (absorption, distribution, metabolism, and elimination) of phenytoin may result in unpredictable changes in drug levels. For example, the phenytoin volume of distribution is higher in obesity, implying a need for higher loading doses but also possibly prolonging the half-life of phenytoin in obese patients 8 . Other patient groups in which pharmacokinetics are altered include the elderly, the critically ill, those with renal or liver failure, or pregnant women 7 . Patients who are on concurrent drugs which interact with phenytoin will also benefit from drug level monitoring. Changing the dosage forms or salt forms (phenytoin sodium versus phenytoin base) and/or interchanging brands may also lead to changes in bioavailability -monitoring the phenytoin level during the period of changeover will also help to optimise the anticonvulsant efficacy.
HOW DO I DOsE PHENYTOIN? sHOULD I ALWAYs GIVE A LOADING DOsE?
The average half-life of oral phenytoin is 22 hours. Using normal maintenance doses, the drug commonly reaches a steady state in 7-10 days 9 . In emergency situations such as status epilepticus when phenytoin must be initiated urgently for a patient, the use of a loading dose will help the Phenytoin can be given intravenously or orally. The loading dose is generally 10-20 mg/kg 10 . If given orally, this dose should be divided into three doses (e.g. 1000 mg given as 400 mg initially, 300 mg two hours later and 300 mg two hours after that) to ensure optimal oral absorption. If given intravenously, the full dose can be given at a maximum rate of 50 mg/min (higher rates can lead to hypotension and cardiac compromise). Subsequent maintenance doses are usually in the range of 5-7 mg/kg/day (300-400 mg/day).
HOW DO I TAKE PHENYTOIN LEVELs?
The Importance of Taking Concurrent Albumin Levels Total serum phenytoin levels reflect both bound and unbound drug. However, as protein-bound phenytoin cannot cross the blood-brain barrier, only free phenytoin is active. In healthy adults, approximately 90% of phenytoin is bound to albumin. Thus, phenytoin levels must be corrected according to albumin levels. 
WHEN sHOULD PHENYTOIN LEVELs bE TAKEN? Scenario 1: Newly Started Patient on Phenytoin
After a patient has received a loading dose of intravenous phenytoin, levels can be checked one hour after the dose. If loading is achieved by oral dosing, phenytoin levels can be checked 24 hours after the last dose 10 . This level can aid in determining maintenance dose or need to reload.
After initiation of a maintenance dose, levels can be taken within three to four days to ensure that the patient's metabolism is not remarkably different from the average literature-derived pharmacokinetic parameters 10 .
Scenario 2: Suspected Non-compliance/ Breakthrough Seizures
Because of the long half-life of phenytoin during long-term administration, the diurnal fluctuation in its plasma concentration is relatively small. The timing of blood samples in relation to the time of dosing is therefore of little importance for correctly interpreting the plasma concentration 4 . Levels can be drawn at the point of admission, regardless of the patient's normal dosing time.
Scenario 3: After Dose Adjustment
In normal healthy subjects after dose adjustment, the phenytoin level should be drawn within six to seven days with subsequent doses of phenytoin adjusted accordingly. In these situations of routine monitoring (unlike the emergency situation of breakthrough seizures in scenario two), it is preferable to draw the phenytoin level just prior to the next dose (a trough level) or at least eight hours after the last dose 10, 11 .
Scenario 4: Suspected Phenytoin Toxicity
Upon suspicion of phenytoin toxicity, a blood level can be drawn immediately and correlated clinically to the patient presenting symptoms. High phenytoin levels with corresponding symptoms will warrant immediate discontinuation of phenytoin. A second phenytoin level may be useful to guide when to restart phenytoin. The lapse time in rechecking the phenytoin level should be determined by how high the first toxic level was, as phenytoin clearance dramatically slows with very toxic concentrations.
WHAT DO I DO WITH THEsE VALUEs?
The reference range for corrected phenytoin is 10-20 mg/dL 9 . When it comes to TDM of anti-epileptic drugs, there is a principle which says: "Treat the patient, not the numbers". Certain patients may not reach the recommended reference range yet remain seizure-free, while other patients may exhibit concentration-related side effects within the normal range. It is not recommended to increase the dose of phenytoin in patients who are seizurefree with low therapeutic levels. Conversely, the dose should be decreased in patients exhibiting symptoms of phenytoin toxicity with "therapeutic" levels. This brings to light the importance of establishing individual therapeutic concentrations for different patients.
How Often Should I Check Phenytoin Levels in a Stable Patient -i.e. in the Outpatient Setting?
Depending on the state of the patient, phenytoin levels are generally monitored at 3-to 12-months intervals 10 . Generally, situations which alter phenytoin pharmacokinetics (e.g. body weight changes, initiation of interacting drugs, changes in renal or liver function) should prompt the physician to revisit the phenytoin regimen and review the need to check drug levels.
How Much Should I Increase the Phenytoin Dose if my Patient is not Responding to Treatment?
Guidelines for dosing adjustments based on phenytoin plasma concentrations have been proposed for adults with epilepsy without clinically significant renal or hepatic disease: for plasma phenytoin concentrations less than 7 µg/ml, a dosage increase of 100 mg/day is recommended; for plasma concentrations between 7 and 12 µg/ ml, the dose may be increased by 50 mg/day; if the plasma concentration is greater than 12 µg/ ml, the dose may increase by 30 mg/day 9 . Dosage increases when the plasma level is above 16 µg/ml should only be done with caution as even a small increase may result in toxicity 9 .
Dose changes should be more conservative in patients with reduced protein binding (e.g. in hypoalbuminemia or in renal impairment) as changes in drug concentration will be exaggerated in these cases.
OTHEr MONITOrING PArAMETErs FOr PHENYTOIN THErAPY
Besides monitoring therapeutic drug levels of phenytoin when such monitoring is of clinical value, there are other parameters which should be considered for all patients on phenytoin therapy.
Monitoring full blood count and liver function tests as well as for any suicidality (suicidal thoughts, depression, behavioural changes) should be performed on a routine basis 10 .
HOW DO I MANAGE ADVErsE EFFEcTs DUE TO PHENYTOIN? WHEN sHOULD I sWITcH MY PATIENT TO ANOTHEr ANTI-EPILEPTIc DrUG?
The complex pharmacokinetics of phenytoin and the need to titrate phenytoin dosage based on drug levels and patient response should not be a deterrent to using phenytoin for seizure control. Phenytoin, when used appropriately, is safe and has well-documented efficacy for many seizure types.
Dose-related adverse effects (Table 1) are common during initiation of therapy, but may improve or resolve over time, even without a change in dose 12 . Titration of dosage regimen based on phenytoin levels may also help with dose-related adverse effects, to achieve an effective drug level with tolerable adverse effects.
The main reason for switching from phenytoin would usually be as a result of non-dose related adverse reactions. Idiosyncratic reactions usually manifest within the first few weeks or months of therapy 12 , and patients newly started on phenytoin should be counselled to be vigilant in looking out for adverse effects and to raise any concerns quickly.
Hypersensitivity manifesting as cutaneous reactions ranging from rash, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms, may warrant discontinuation of phenytoin 9 . Cross-sensitivity of skin rash has been noted between phenytoin and carbamazepine 13 , and carbamazepine should be avoided in patients with rash due to phenytoin. Of note, phenytoinrelated SJS seems to be increased in Asians with the HLA-B*1502 allele 14 .
Hepatitis may result from phenytoin use. Generally, sustained transaminitis or clinical hepatitis (jaundice, hepatomegaly, acute liver failure) should spur a change of anti-epileptic 9 . When considering alternative anti-epileptics in this situation, precautions with pre-existing liver impairment may need to be considered, for example, valproate or carbamazepine (both of which are metabolised hepatically).
Drug interactions between phenytoin and other crucial drugs may warrant switching to a non-interacting drug. Phenytoin induces cytochrome P450 enzyme activity, and may alter the effects of medicines such as immunosuppressants (tacrolimus, cyclosporine) and anticoagulants (warfarin, rivaroxaban) 15 . Where no alternative to these medications exist, phenytoin may need to be switched to an alternative non-interacting drug.
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